Free Trial

HilleVax Q4 2023 Earnings Report

HilleVax logo
$1.86 +0.03 (+1.64%)
(As of 12/20/2024 05:51 PM ET)

HilleVax EPS Results

Actual EPS
-$0.78
Consensus EPS
-$0.80
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

HilleVax Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HilleVax Announcement Details

Quarter
Q4 2023
Time
N/A
DeFi Coin on Verge of Breakout! (Ad)

The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.

Claim your FREE book now before it's too late!

HilleVax Earnings Headlines

Reviewing Fate Therapeutics (NASDAQ:FATE) & HilleVax (NASDAQ:HLVX)
DeFi Coin on Verge of Breakout!
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
HilleVax Reports Q3 Financial Results Amid Strategic Planning
See More HilleVax Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HilleVax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HilleVax and other key companies, straight to your email.

About HilleVax

HilleVax (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

View HilleVax Profile

More Earnings Resources from MarketBeat

Upcoming Earnings